Roche files Tecentriq, Avastin combo as a liver cancer therapyRoche has filed for approval of a two-drug combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular Share XRoche files Tecentriq, Avastin combo as a liver cancer therapyhttps://pharmaphorum.com/news/roche-files-tecentriq-avastin-combo-as-a-liver-cancer-therapy/
FDA decision on Opdivo/Yervoy in liver cancer due next MarchThe FDA has started a priority review of Bristol-Myers Squibb’s immuno-oncology combination of Opdivo and Yervoy in liver Share XFDA decision on Opdivo/Yervoy in liver cancer due next Marchhttps://pharmaphorum.com/news/fda-decision-on-opdivo-yervoy-in-liver-cancer-due-next-march/
Sillajen explains Pexa-Vec trial failure – it was the rescue medsSouth Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase Share XSillajen explains Pexa-Vec trial failure – it was the rescue medshttps://pharmaphorum.com/news/sillajen-explains-pexa-vec-trial-failure-it-was-the-rescue-meds/
BMS has another Opdivo setback after liver cancer trial failureBristol-Myers Squibb’s cancer immunotherapy Opdivo has suffered another setback after it failed to improve on standard care in Share XBMS has another Opdivo setback after liver cancer trial failurehttps://pharmaphorum.com/news/bms-has-another-opdivo-setback-after-liver-cancer-trial-failure/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
Lilly gets fifth use for Cyramza with FDA liver cancer nodEli Lilly’s Cyramza has a new string to its bow after the FDA approved it as a second-line Share XLilly gets fifth use for Cyramza with FDA liver cancer nodhttps://pharmaphorum.com/news/lilly-gets-fifth-use-for-cyramza-with-fda-liver-cancer-nod/
Exelixis’ Cabometyx approved in second-line liver cancer in USExelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a Share XExelixis’ Cabometyx approved in second-line liver cancer in UShttps://pharmaphorum.com/news/exelixis-cabometyx-approved-in-second-line-liver-cancer-in-us/
Ipsen warns over medicine supplies amid Brexit uncertaintyFrance’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma Share XIpsen warns over medicine supplies amid Brexit uncertaintyhttps://pharmaphorum.com/news/ipsen-warns-over-medicine-supplies-amid-brexit-uncertainty/
AZ begins liver cancer immunotherapy tie-up with AVEOAstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in Share XAZ begins liver cancer immunotherapy tie-up with AVEOhttps://pharmaphorum.com/news/az-begins-liver-cancer-immunotherapy-tie-up-with-aveo/
